CRDF
Cardiff Oncology, Inc.
$1.64
+2.50%
2026-05-08
About Cardiff Oncology, Inc.
Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies for the treatment of various cancers in the United States. Its lead drug candidate is Onvansertib, an oral and selective polo-like kinase 1 inhibitor for treating RAS-mutated metastatic colorectal cancer. The company also focuses on the clinical program in indications, such as investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma, small cell lung cancer, metastatic triple negative breast cancer, and chronic myelomonocytic leukemia; CRDF-004, a Phase 2 open-label randomized multi-center clinical trial of onvansertib in combination with FOLFIRI and bevacizumab or FOLFOX and bevacizumab for the treatment of patients confirmed metastatic and unresectable colorectal cancer in patients with a KRAS or NRAS mutation; and TROV-054, a Phase 1b/2 single-arm clinical trial in KRAS-mutated metastatic colorectal cancer. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was founded in 1999 and is headquartered in San Diego, California.
Key Fundamentals
Forward P/E
-2.31
EPS (TTM)
$-0.69
ROE
-71.5%
Revenue Growth (YoY)
60.9%
Profit Margin
0.0%
Debt/Equity
1.83
Price/Book
2.44
Beta
1.36
Market Cap
$110.8M
Avg Volume (10D)
623K
Recent Breakout Signals
No recent breakout signals detected for CRDF.
Recent Price Range (60 Days)
60D High
$2.06
60D Low
$1.54
Avg Volume
678K
Latest Close
$1.64
Get breakout alerts for CRDF
Sign up for Breakout Scanner to receive daily notifications when CRDF triggers breakout signals. Build custom AI screeners and backtest strategies.
Start Free Trial7-day free trial. No card required.
Cardiff Oncology, Inc. (CRDF) is listed on the NASDAQ (NASDAQ). Breakout Scanner monitors CRDF daily for breakout patterns including long-term ceiling breakouts, momentum breakouts, and near-breakout watch setups. CRDF operates in the Healthcare sector within the Biotechnology industry. Data is provided for informational purposes only and does not constitute financial advice.